Personalis Inc (PSNL) - News Archive

In a landmark development for breast cancer patients and the realm of precision oncology, Personalis, Inc. (Nasdaq: PSNL) has announced Medicare coverage for its ultrasensitive NeXT Personal test, designed for monitorin...

In a pioneering leap for precision oncology, Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics, has announced a promising collaboration with a renowned team from Yale Cancer Center. Together, they are embar...

In a significant advancement for oncology, Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomic solutions, has unveiled pivotal new data from a landmark phase 3 clinical trial, NeoADAURA, in collaboration with...

Personalis and Tempus Expand Collaboration to Introduce Advanced Cancer Recurrence Testing for Colorectal Cancer PatientsIn a significant advancement for oncology diagnostics, Personalis, Inc. (Nasdaq: PSNL) has announc...

Investments and Collaborations Propel Personalis Inc. into a New Strategic Era FREMONT, Calif. In a significant advance towards a burgeoning future, Personalis, Inc. (NASDAQ: PSNL), a key player in the biotechnology lan...

In an industry characterized by relentless innovation, Personalis Inc. (NASDAQ: PSNL) and Tempus AI, Inc. (NASDAQ: TEM) have embarked on a significant expansion of their collaboration, heralding a new era in biomarker-d...

Advancements in Cancer Monitoring: Evaluating Personalis Inc. Amid Financial ChallengesThe landscape of cancer diagnostics and monitoring continues to evolve, with innovative technologies playing a pivotal role in early...

In a significant development for cancer diagnostics, biotech companies Personalis, Inc. and Tempus AI, Inc. have expanded their collaboration to bring ultra-sensitive minimal residual disease (MRD) testing to market. Th...

In a significant advancement within the oncology landscape, Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) have announced an expanded collaboration aimed at commercializing ultra-sensitive minimal res...

In a significant move within the healthcare landscape, Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) have announced an expansion of their collaboration aimed at bringing ultra-sensitive minimal resid...

In the rapidly changing landscape of precision medicine, companies are seeking innovative ways to enhance the diagnosis and treatment of cancer. A striking development in this arena is the expanded collaboration between...

Personalis Inc (NASDAQ: PSNL) has experienced a tumultuous journey in recent years, leaving shareholders disheartened, but recent developments suggest a potential rebound. Despite significant losses over the past three...

In the financial world, share performance is closely scrutinized to determine the success and growth of a company. Personalis Inc, a prominent player in the biotechnology industry, has experienced a lackluster performan...

Personalis Inc (NASDAQ: PSNL), a leader in advanced genomics for cancer research, has recently experienced a sell-off in its shares. This article aims to delve into the events and factors that may have contributed to th...

Personalis, Inc., a pioneer in advanced genomics for cancer, is making significant strides in the field of precision oncology with its revolutionary NeXT Personal liquid biopsy assay. Recent announcements by the company...

Integrating Personalis NeXT Test Delivers Cutting-Edge Advances in Early-Stage Breast Cancer Recurrence Detection and Immunotherapy MonitoringFremont, Calif. - Personalis, Inc. (Nasdaq: PSNL) unveiled groundbreaking dat...

By FREMONT, Calif. Personalis, Inc. (Nasdaq: PSNL) has unveiled groundbreaking data demonstrating the efficacy of its NeXT Personal test at the American Society for Clinical Oncology (ASCO) annual meeting in Chicago, IL...

Tempus and Personalis Launch Commercialization of Advanced Cancer MRD Testing with NeXT Personal Dx AssayFREMONT, Calif. Personalis, Inc. (Nasdaq: PSNL), a pioneering force in advanced genomics for precision oncology, h...